Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

doi:10.3748/wjg.v26.i16.1888

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10521)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

960

WORD

237

HTML

7036

Figures (1-4)

361

Tables (1-3)

301

Sum=8895

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

732

Download

894

Sum=1626

Apr 28, 2020 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Apr 28, 2020; 26(16): 1888-1900
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1888

Full Size Figure Download Figure

Figure 2 Radiological tumor response between sorafenib and lenvatinib according to RECIST 1. 1 criteria, reported in the REFLECT trial. RECIST: Response Evaluation Criteria for Solid Tumors; ORR: Objective response rate.

Citation: Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900
URL: https://www.wjgnet.com/1007-9327/full/v26/i16/1888.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i16.1888